Yupelri® (revefenacin)
COPD
Key Facts
About Cleo Life Sciences
Founded in 2004, Cleo Life Sciences offers a unique hybrid model combining strategic CMC consulting with hands-on, small-scale laboratory prototyping to de-risk and accelerate pharmaceutical development. The company leverages its founder's deep industry experience, having contributed to the CMC development of five commercial drugs and over 60 clinical-stage candidates. Its mission is to transform pharmaceutical development by enabling earlier, faster, and more efficient product and process development for its biopharma clients.
View full company profileAbout Theravance Biopharma
Theravance Biopharma is a commercial-stage biotech focused on transforming treatment for serious respiratory diseases through organ-selective medicines. Its core achievement is the FDA approval and commercialization of YUPELRI® (revefenacin) for COPD, validating its multivalent pharmacology platform. The company's strategy involves leveraging this platform to advance a pipeline of targeted respiratory therapeutics while managing commercial execution through a partnership with Viatris.
View full company profileTherapeutic Areas
Other COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| Spiro Neuromodulation System | Spiro Medical | Phase 2 |
| VL-PX10 & VL-P22 | Vitti Labs | Phase 2 |
| Solrikitug | Uniquity Bio | Phase 2 |
| CAL-4 | Calyxha Biotechnologies | Discovery |
| OligoG (Inhaled) | Algipharma | Phase 2 |
| Digital Biomarker for COPD | electronRx | Early Development |
| Tozorakimab | AstraZeneca | Phase III |
| Eclira Genuair (Acidinium Bromide) | KYORIN Pharmaceutical | Marketed |
| ANORO ELLIPTA | Innoviva | Commercial |
| GB-0895 | Generate Biomedicines | Phase 1 |